Merck stock (MRK) heads into a holiday pause as FDA fast-review program draws scrutiny
Merck & Company, Inc. shares closed Friday at $108.83, slipping 1.9%. U.S. markets will be shut Monday for Martin Luther King Jr. Day.
Novartis stock price: NOVN ends higher on FDA Breakthrough tag for Sjögren’s drug ianalumab — what to watch next week
Novartis shares rose close to 1% on Friday after the Swiss pharma giant announced that U.S. regulators had granted a Breakthrough Therapy designation to ianalumab, its drug candidate for Sjögren’s disease. The stock finished at 115.60 Swiss francs on the SIX Swiss Exchange.
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next
AbbVie’s stock dropped on Friday after partner Genmab announced that a late-stage trial of epcoritamab failed to meet its primary endpoint of improving overall survival in blood cancer patients. AbbVie closed at $214.35, down 1.1%. Genmab’s U.S.-listed shares tumbled over 7%. The companies said they still expect data from two other late-stage epcoritamab trials in 2026, including studies combining the drug with standard chemotherapy and Bristol Myers Squibb’s Revlimid.
Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week
Shares of Novo Nordisk jumped 6.49% to 388.90 Danish crowns on Friday, marking their biggest daily gain in weeks. The surge came after new demand signals for its Wegovy obesity drug and a UK approval for a higher Wegovy dose brought the stock back into focus for investors.
Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom
Pfizer Inc shares slipped 0.93% to $25.65 on Friday. Reuters reported that some drugmakers harbor quiet concerns over a White House-backed fast FDA review program, fearing it could increase legal risks if a rushed process overlooks safety problems. Pfizer has reportedly considered joining the initiative, according to Reuters.
Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play
Shares of Novo Nordisk A/S Class B jumped 6.5%, finishing Friday at 388.9 Danish crowns. The late-week surge put the stock in a stronger position ahead of Monday’s market open. Trading volume hit roughly 13.9 million shares amid a session that shifted alongside the news cycle.
Roche stock price in focus: Goldman flips to neutral as ROG heads into Jan. 29 results
Roche Holding shares closed Friday 0.93% higher at 348.90 Swiss francs on the Swiss Exchange, a gain of 3.20 francs from Thursday’s finish. Swiss markets remain closed Saturday.
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week
Eli Lilly shares ended Friday up 0.5%, closing at $1,038.40. Investors enter the week anticipating a delayed U.S. regulatory verdict on the drugmaker’s experimental obesity medication.
Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land
Shares of Pfizer Inc closed Friday down 0.9% at $25.65. Investors wrestled with a jumble of policy updates, regulatory filings, and a biotech IPO that dragged Pfizer’s name back into the paperwork spotlight.
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week
Novo Nordisk shares gained 6.5% on Friday, closing at 388.9 Danish crowns, positioning the stock for a notable open Monday. In New York, the company’s ADRs jumped 9.1% to finish at $62.33.
GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results
Shares of GSK plc slipped 1.7% to 1,817 pence on Friday, lagging behind a flat FTSE 100 as volume spiked late in the session. The stock closed 11.7% below its 52-week peak of 2,058 pence reached on Dec. 19. Trading volume hit 12.6 million shares, well above the 50-day average of 8.2 million.
Merck stock price slips as FDA fast-track doubts surface before MRK earnings
Shares of Merck & Co dipped 1.9% Friday, closing at $108.83 following a range of $108.49 to $111.19. The stock kicked off the session at $110.63 with roughly 14.9 million shares traded.
AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next
AbbVie shares slipped 1.1% to close at $214.35 on Friday following mixed late-stage results for its lymphoma treatment, epcoritamab. In after-hours trading, the stock was last seen near $214.66, as U.S. indexes showed little movement.
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang
Eli Lilly shares ticked up about 0.5%, closing at $1,038.40 in after-hours trading Friday, after swinging between $1,019.00 and $1,049.83 during the session. Internal documents reviewed by Reuters revealed the U.S. FDA has pushed back its target decision date for Lilly’s obesity drug orforglipron to April 10. Holly Fernandez Lynch, a health policy professor at the University of Pennsylvania, noted the delay signals the agency remains cautious, essentially saying: “Hold on, we’re not actually sure this product should be allowed on the market.”
Merck stock slips as FDA fast-track questions build and earnings near
Merck & Co shares dropped roughly 1.2% to $109.65 on Friday, erasing earlier gains and settling near the session lows. The stock swung between $108.49 and $111.19 during the day, with around 7.6 million shares changing hands by the afternoon.
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst
AbbVie Inc shares dropped 1.1% to $214.35 Friday afternoon after releasing mixed results from a late-stage trial of its lymphoma drug epcoritamab. The Phase 3 study hit its primary endpoint, showing improved progression-free survival — meaning patients lived longer without their cancer worsening — but it missed a statistically significant gain in overall survival, the company said. AbbVie and partner Genmab said they plan to consult regulators on the next steps.
Eli Lilly stock price edges higher as FDA timeline for obesity pill comes into focus
Eli Lilly shares rose 0.3% to $1,036.46 on Friday morning, after touching as low as $1,019, as investors weighed an updated U.S. regulatory timeline for the company’s experimental obesity pill.
PainReform PRFX stock jumps in premarket after company rebrands as PRF Technologies
PainReform Ltd shares rose in premarket trading on Friday following the company’s announcement that it has rebranded as PRF Technologies Ltd. The microcap firm said the new name signals an expansion beyond its initial focus on pain therapy.
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed
Eli Lilly and Co shares slipped 3.8% in premarket trading Friday, following a wave of regulatory and legal news around its obesity drugs late last week. The stock last traded at $1,032.97.
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10
Eli Lilly and Co shares dropped 3.8% to $1,032.97 in after-hours trading Thursday after Reuters reported the FDA is now aiming for an April 10 decision on Lilly’s experimental obesity drug, orforglipron. The report also revealed delays in other drugs under a new fast-track review program, following safety and efficacy concerns raised by FDA scientists.